Beermann B, Groschinsky-grind M
Eur J Clin Pharmacol. 1978 May 31;13(3):195-201. doi: 10.1007/BF00609982.
Nine previously untreated hypertensive patients (WHO Stage I and II) were given hydrochlorothiazide (hct) 12.5, 25, 50 and 75 mg for two weeks after an initial four week period of placebo treatment. Blood pressure recordings were made casually and after 30 min rest in lying, sitting and standing positions. Plasma concentrations of the drug were measured by GLC. A significant decrease in BP was seen during treatment with hct 12.5 mg except in the casual standing position. Doubling of the dose twice produced very little further decrease in BP. The mean steady state concentration was 111 ng.ml-1 during treatment with hct 75 mg. A linear relationship was found between the plasma concentration of hct at 0 and 5 h and the various dose level of hct. No relation was found between plasma concentration and reduction in blood pressure.
九名既往未经治疗的高血压患者(世界卫生组织Ⅰ期和Ⅱ期)在经过为期四周的安慰剂治疗后,接受了12.5毫克、25毫克、50毫克和75毫克的氢氯噻嗪(hct)治疗,为期两周。在随意状态下以及静卧、坐姿和站立休息30分钟后测量血压。通过气相色谱法测量药物的血浆浓度。除了随意站立位外,在使用12.5毫克hct治疗期间血压显著下降。剂量加倍两次后血压进一步下降很少。在使用75毫克hct治疗期间,平均稳态浓度为111纳克·毫升⁻¹。发现hct在0和5小时时的血浆浓度与hct的不同剂量水平之间存在线性关系。未发现血浆浓度与血压降低之间存在关联。